NASDAQ:BEAM Beam Therapeutics (BEAM) Stock Forecast, Price & News $23.60 +0.59 (+2.56%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$22.80▼$24.2850-Day Range$23.01▼$32.4652-Week Range$22.52▼$54.30Volume843,543 shsAverage Volume876,288 shsMarket Capitalization$1.87 billionP/E RatioN/ADividend YieldN/APrice Target$63.82 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Beam Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside170.4% Upside$63.82 Price TargetShort InterestBearish16.58% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 6 Articles This WeekInsider TradingSelling Shares$5.03 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($5.06) to ($5.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 starsMedical Sector693rd out of 964 stocksBiological Products, Except Diagnostic Industry112th out of 157 stocks 4.4 Analyst's Opinion Consensus RatingBeam Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $63.82, Beam Therapeutics has a forecasted upside of 170.4% from its current price of $23.60.Amount of Analyst CoverageBeam Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.58% of the outstanding shares of Beam Therapeutics have been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.Change versus previous monthShort interest in Beam Therapeutics has recently increased by 0.54%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BEAM. Previous Next 1.9 News and Social Media Coverage News SentimentBeam Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Beam Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 7 people have searched for BEAM on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,030,209.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions80.64% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Beam Therapeutics are expected to decrease in the coming year, from ($5.06) to ($5.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Beam Therapeutics (NASDAQ:BEAM) StockBeam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Read More BEAM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BEAM Stock News HeadlinesSeptember 26, 2023 | msn.comFuture of payments should be as much like cash as possible: Crypto wallet Beam CEOSeptember 24, 2023 | americanbankingnews.comHead-To-Head Analysis: BioCardia (NASDAQ:BCDA) versus Beam Therapeutics (NASDAQ:BEAM)September 27, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 21, 2023 | benzinga.comImage-Guided Radiation Therapy Market worth $2.4 billion by 2028September 21, 2023 | markets.businessinsider.comCentre for Ion Beam Applications at NUS designated as IAEA's first Collaborating Centre in SingaporeSeptember 21, 2023 | bizjournals.comBeam Benefits raises $40M at increased valuation despite tough VC climateSeptember 7, 2023 | finance.yahoo.comBeam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing MutationSeptember 5, 2023 | markets.businessinsider.comBeam Therapeutics' Role In Gene-Editing 2.0 Revolution: First U.S. Patient Treated With Base-Edited Cell TherapySeptember 27, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 1, 2023 | msn.comFounder of Drayer Physical Therapy launches new businessAugust 30, 2023 | markets.businessinsider.comCantor Fitzgerald Sticks to Its Buy Rating for Beam Therapeutics (BEAM)August 29, 2023 | msn.comMarquette County Conservation District, Barrel + Beam host Composting 101 workshopAugust 29, 2023 | msn.comCantor Fitzgerald Reiterates Beam Therapeutics (BEAM) Overweight RecommendationAugust 29, 2023 | businesswire.comThe Hartford Enhances Employee Benefits For Small Businesses Through New Relationship With Beam BenefitsAugust 28, 2023 | technews.tmcnet.comEmpyrean, MagCorp, and MetOx Announce Strategic Collaboration Agreement on the Scale-up of Novel Technology for Radiation Therapy and Cancer TreatmentAugust 26, 2023 | finance.yahoo.com3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall StreetAugust 25, 2023 | yahoo.comThe New Little Book Chapter 7 Is Unlike Any Other Jim Beam Whiskey We’ve TriedAugust 11, 2023 | finance.yahoo.comDown -20.85% in 4 Weeks, Here's Why Beam Therapeutics Inc. (BEAM) Looks Ripe for a TurnaroundAugust 11, 2023 | msn.comCredit Suisse Maintains Beam Therapeutics (BEAM) Neutral RecommendationAugust 9, 2023 | msn.comTremont man walking to raise awareness about proton beam cancer therapyAugust 9, 2023 | markets.businessinsider.comCredit Suisse Maintains Neutral Rating for Beam Therapeutics: Here's What You Need To KnowAugust 9, 2023 | markets.businessinsider.comBernstein Keeps Their Hold Rating on Beam Therapeutics (BEAM)August 9, 2023 | markets.businessinsider.comCiti Remains a Buy on Beam Therapeutics (BEAM)August 8, 2023 | msn.comBeam Therapeutics GAAP EPS of -$1.08 beats by $0.31, revenue of $20.12M beats by $3.27MAugust 8, 2023 | markets.businessinsider.comBeam Therapeutics Q2 Loss Widens But Beats EstimatesAugust 8, 2023 | finance.yahoo.comBeam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial ResultsAugust 4, 2023 | msn.comRemnant 2: How to Get The Plasma Cutter (Beam Rifle)See More Headlines Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BEAM Company Calendar Last Earnings8/08/2023Today9/27/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BEAM CUSIPN/A CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees532Year Founded2017Price Target and Rating Average Stock Price Forecast$63.82 High Stock Price Forecast$105.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside+170.4%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($4.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-289,090,000.00 Net Margins-408.13% Pretax Margin-372.07% Return on Equity-43.32% Return on Assets-24.33% Debt Debt-to-Equity RatioN/A Current Ratio5.22 Quick Ratio5.22 Sales & Book Value Annual Sales$60.92 million Price / Sales30.68 Cash FlowN/A Price / Cash FlowN/A Book Value$10.41 per share Price / Book2.27Miscellaneous Outstanding Shares79,200,000Free Float75,715,000Market Cap$1.87 billion OptionableNot Optionable Beta1.62 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. John M. Evans M.B.A. (Age 45)CEO & Director Comp: $1.11MDr. Giuseppe Ciaramella Ph.D. (Age 54)Pres Comp: $933.2kMs. Terry-Ann Burrell M.B.A. (Age 46)CFO & Treasurer Comp: $711.15kDr. Feng Zhang Ph.D.Co-FounderDr. David R. Liu Ph.D.Co-FounderDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Nicole Gaudelli Ph.D.Co-FounderDr. Alexis Komor Ph.D.Co-FounderDr. Manmohan Singh Ph.D.Chief Technology OfficerDr. Gopi Shanker Ph.D.Chief Scientific OfficerMore ExecutivesKey CompetitorsArcellxNASDAQ:ACLXRecursion PharmaceuticalsNASDAQ:RXRXVericelNASDAQ:VCELSpringWorks TherapeuticsNASDAQ:SWTXBioCryst PharmaceuticalsNASDAQ:BCRXView All CompetitorsInsiders & InstitutionsBarclays PLCBought 28,903 shares on 9/21/2023Ownership: 0.182%Virginia Retirement Systems ET ALBought 15,900 shares on 8/22/2023Ownership: 0.020%California State Teachers Retirement SystemBought 525 shares on 8/21/2023Ownership: 0.093%Nuveen Asset Management LLCSold 30,057 shares on 8/16/2023Ownership: 0.216%Royal Bank of CanadaBought 1,408 shares on 8/15/2023Ownership: 0.029%View All Insider TransactionsView All Institutional Transactions BEAM Stock - Frequently Asked Questions Should I buy or sell Beam Therapeutics stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BEAM shares. View BEAM analyst ratings or view top-rated stocks. What is Beam Therapeutics' stock price forecast for 2023? 10 Wall Street research analysts have issued 12-month price targets for Beam Therapeutics' shares. Their BEAM share price forecasts range from $35.00 to $105.00. On average, they predict the company's stock price to reach $63.82 in the next year. This suggests a possible upside of 170.4% from the stock's current price. View analysts price targets for BEAM or view top-rated stocks among Wall Street analysts. How have BEAM shares performed in 2023? Beam Therapeutics' stock was trading at $39.11 at the beginning of 2023. Since then, BEAM stock has decreased by 39.7% and is now trading at $23.60. View the best growth stocks for 2023 here. When is Beam Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our BEAM earnings forecast. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.08) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.34. The firm had revenue of $20.12 million for the quarter, compared to analyst estimates of $17.32 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 43.32% and a negative net margin of 408.13%. The firm's revenue was up 20.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.02) earnings per share. What ETFs hold Beam Therapeutics' stock? ETFs with the largest weight of Beam Therapeutics (NASDAQ:BEAM) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM), ARK Innovation ETF (ARKK), Horizon Kinetics Medical ETF (MEDX), Jacob Forward ETF (JFWD) and WisdomTree BioRevolution Fund (WDNA). What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC). When did Beam Therapeutics IPO? (BEAM) raised $101 million in an initial public offering on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Beam Therapeutics' stock symbol? Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM." Who are Beam Therapeutics' major shareholders? Beam Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.00%), BlackRock Inc. (8.02%), Temasek Holdings Private Ltd (5.45%), State Street Corp (4.53%), Geode Capital Management LLC (1.67%) and Deep Track Capital LP (1.66%). Insiders that own company stock include Amy Simon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell. View institutional ownership trends. How do I buy shares of Beam Therapeutics? Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Beam Therapeutics' stock price today? One share of BEAM stock can currently be purchased for approximately $23.60. How much money does Beam Therapeutics make? Beam Therapeutics (NASDAQ:BEAM) has a market capitalization of $1.87 billion and generates $60.92 million in revenue each year. The company earns $-289,090,000.00 in net income (profit) each year or ($4.51) on an earnings per share basis. How many employees does Beam Therapeutics have? The company employs 532 workers across the globe. Does Beam Therapeutics have any subsidiaries? The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..Read More How can I contact Beam Therapeutics? Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.beamtx.com. The company can be reached via phone at 857-327-8775 or via email at investors@beamtx.com. This page (NASDAQ:BEAM) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.